TL;DR
Most advice on using charts effectively stops at picking the right chart type. That's necessary but not sufficient once the data is clinical, regulatory, or investor-facing - because now the chart also has to survive a KOL's scrutiny, a payer's HTA review, or an investor's due diligence, without overclaiming or hiding uncertainty.
A chart is effective when a specific audience reaches a specific correct conclusion faster than they would from the underlying data table - and nothing more or less than that conclusion. That's a higher bar than most presentation advice implies.
Most guidance on charts in presentations stops at "pick the right chart type" and "cut the clutter." That's correct, but it's the easy half of the problem. The harder half shows up the moment the data is clinical, scientific, or regulatory - because now the chart isn't just competing for attention, it's being scrutinized by someone who knows the field better than you do.
I review chart-heavy decks for Medical Affairs, HEOR, and biotech clients constantly, and the failure pattern is consistent: the chart is visually clean and still wrong, because clean and accurate are different problems, and most design guidance only solves the first one.
The Effectiveness Test: Three Questions Before Any Chart Goes on a Slide
What conclusion does this chart need to prove?
Not what does this chart show - what does it need to prove for the argument on this specific slide. A chart that shows five things accurately is less effective than one that proves one thing unmistakably.
What does this audience already know how to read?
A forest plot is instantly legible to a KOL and functionally unreadable to a generalist investor. Matching chart type to argument is step one; matching it to audience literacy is step two.
What could this chart imply that the data does not support?
A truncated y-axis makes a modest effect look dramatic. A mean line without a confidence interval makes uncertain data look settled. A subgroup analysis can imply significance it may not have.
Where Clinical and Scientific Data Breaks Generic Chart Advice
Statistical uncertainty gets designed away.
Confidence intervals, error bars, and p-values are often the first thing cut when a chart looks cluttered. For a clinical efficacy chart going in front of a KOL or payer committee, removing the uncertainty band is not simplification - it is a misrepresentation of what the data actually says.
Color gets used for branding instead of grouping.
General design guidance says to use an accent color to draw the eye. In a chart with overlapping cohorts, using near-identical brand colors instead of maximally distinguishable ones makes the chart harder to read the more it is scrutinized.
The legend gets treated as an afterthought.
A legend tucked in a bottom corner works fine when the audience skims. It fails when the audience is cross-referencing plot lines against subgroup populations in real time, which is exactly what happens when a KOL evaluates a multi-arm trial result live in the room.
None of these are chart-type problems. They are chart-discipline problems specific to data where the audience's job is to find the flaw, not just absorb the takeaway.
A Working Standard for Clinical and Scientific Charts
Show uncertainty by default, not by exception.
Confidence intervals, error bars, or a stated n= belong on the chart itself, not in a footnote the audience has to go looking for.
Use color for distinguishability, not brand consistency.
When cohorts or arms need to be told apart at a glance, maximally different colors outperform on-brand color families every time.
Cite the source and the n on the slide.
A chart without a visible source line and sample size reads as a claim without evidence to anyone trained to check for it.
Separate the primary endpoint from everything else.
Size, position, and color should make the hierarchy of evidence obvious without a caption explaining it.
Where to Go Deeper
This is the general standard - the questions and rules that apply across clinical, HEOR, and investor-facing charts. Two of our other guides go deeper on the specific chart types this standard applies to.
Clinical Data Visualization Playbook
Forest plots, Kaplan-Meier survival curves, and formatting conventions payer and HTA reviewers expect.
View guideChart Presentation Ideas
A broader reference on chart type selection outside clinical data specifically - bar, line, waterfall, and other formats.
View guideMSL Slide Deck Design
How chart discipline fits inside a full Medical Affairs or MSL deck, not just a single slide.
View guideMedical Affairs Presentation Design
MLR-ready deck systems for KOL meetings, advisory boards, HEOR submissions, congresses, and field medical teams.
View guideFAQ
Start with the one conclusion the chart needs to prove, choose the chart type your specific audience already knows how to read, and check what the visual implies that the underlying data may not fully support - a truncated axis or a missing confidence interval can make a chart technically accurate and still misleading.
It shows statistical uncertainty by default, uses color to distinguish cohorts rather than to match brand guidelines, cites the source and sample size on the slide itself, and visually separates the primary endpoint from secondary or subgroup findings so the hierarchy of evidence is unmistakable.
For clinical, regulatory, or investor-facing data, yes, as the default. Removing them to reduce visual clutter removes information a scientifically literate reviewer will expect to see and will notice is missing.
Giving a subgroup or secondary analysis the same visual weight as the primary endpoint. It implies a level of statistical confidence the study may not have been powered to support, and it is usually the first thing a KOL or HTA reviewer will flag.
